Loading...
XNASNEPH
Market cap15mUSD
Dec 31, Last price  
1.47USD
1D
-0.68%
1Q
-6.37%
Jan 2017
297.30%
Name

Nephros Inc

Chart & Performance

D1W1MN
XNAS:NEPH chart
P/E
—
P/S
1.09
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
8.69%
Rev. gr., 5y
20.15%
Revenues
14m
+42.74%
138,4062,424,483793,4891,196,0001,473,0002,661,0002,938,0002,214,0001,807,0001,740,0001,748,0001,944,0002,320,0003,809,0005,687,00010,334,0008,561,00010,404,0009,975,00014,238,000
Net income
-2m
L-78.50%
-7,596,480-5,468,177-8,012,911-26,356,000-6,337,000-2,026,000-1,933,000-2,360,000-3,262,000-3,698,000-7,371,000-3,088,000-3,032,000-809,000-3,402,000-3,179,000-4,724,000-4,165,000-7,324,000-1,575,000
CFO
827k
P
-7,838,981-5,052,194-7,299,597-7,434,000-5,725,000-2,612,000-1,292,000-1,296,000-1,547,000-3,583,000-2,495,000-3,815,000-2,112,000-77,000-3,662,000-2,276,000-6,903,000-1,417,000-3,234,000827,000
Earnings
Mar 05, 2025

Profile

Nephros, Inc. develops and sells high performance water solutions to the medical and commercial markets in the United States. The company operates in three segments: Water Filtration, Pathogen Detection, and Renal Products. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. The company also develops and sells real-time water testing systems to provide actionable data on waterborne pathogens; and medical device products for patients with renal disease, including a 2nd generation hemodiafiltration system for the treatment of patients with end stage renal disease. In addition, it offers water filters that improve the taste and odor of water, as well as reduce biofilm, bacteria, and scale build-up in downstream equipment under the Nephros and AETHER brands for the food service, hospitality, convenience store, and health care markets. The company was incorporated in 1997 and is headquartered in South Orange, New Jersey.
URL
https://www.nephros.com/
IPO date
Sep 21, 2004
Employees
27
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
14,238
42.74%
9,975
-4.12%
Cost of revenue
6,706
6,499
Unusual Expense (Income)
NOPBT
7,532
3,476
NOPBT Margin
52.90%
34.85%
Operating Taxes
3,047
Tax Rate
87.66%
NOPAT
7,532
429
Net income
(1,575)
-78.50%
(7,324)
75.85%
Dividends
Dividend yield
Proceeds from repurchase of equity
132
BB yield
-1.11%
Debt
Debt current
892
387
Long-term debt
4,616
1,727
Deferred revenue
Other long-term liabilities
(1,390)
Net debt
1,201
(1,520)
Cash flow
Cash from operating activities
827
(3,234)
CAPEX
(75)
(137)
Cash from investing activities
(75)
(137)
Cash from financing activities
(79)
34
FCF
7,362
1,706
Balance
Cash
4,307
3,634
Long term investments
Excess cash
3,595
3,135
Stockholders' equity
(144,396)
(139,532)
Invested Capital
155,036
149,489
ROIC
4.95%
0.29%
ROCE
70.79%
34.91%
EV
Common stock shares outstanding
10,386
10,297
Price
3.46
199.00%
1.16
-80.39%
Market cap
35,936
201.58%
11,916
-79.84%
EV
37,137
13,685
EBITDA
7,746
3,827
EV/EBITDA
4.79
3.58
Interest
2
20
Interest/NOPBT
0.03%
0.58%